Gabaglia Claudia

Gabaglia Claudia, a woman-owned small disadvantaged business operating as a sole proprietor, provides specialized medical case review and expert analysis services to the Department of Health and Human Services as a prime contractor under a single-award blanket purchase agreement. The vendor is based in San Diego, California, and operates exclusively within federal compensation programs for vaccine and countermeasure injury claims.

Gabaglia Claudia holds a specialized market position focused narrowly on medical case review for two linked HRSA programs. The vendor's entire footprint—all 61 awards across a recent 11-year span—flows through the Health Resources and Services Administration's Vaccine Injury Compensation Program (VICP) and Countermeasures Injury Compensation Program (CICP). Work involves examining individual petitioner case files, rendering professional medical opinions, and providing detailed expert analysis to support HRSA's adjudication of compensation claims for alleged vaccine and countermeasure injuries. The vendor operates under primary NAICS 621111 (Offices of Physicians except Mental Health Specialists) and PSC Support–Professional–Expert Witness, with all work performed in San Diego.

The vendor holds a $7.5 million single-award BPA with HRSA established June 2, 2022, through June 1, 2027. HRSA has issued approximately 58 task-order calls against this BPA since establishment, with individual call values ranging from approximately $4,375 to $24,500 and most calls firm fixed-price. Recent representative calls include $52,500 (September 10, 2026), $24,500 (August 13, 2026), $24,500 (July 27, 2026, designated total small business set-aside), and multiple additional calls throughout 2025 and 2026. The vendor places no work through secondary BPA vehicles; three legacy blanket purchase agreements (75R60222A00024, HHSH250201500040B, and 75R60219A00060) carry legacy task orders but account for a combined $1.04 million of the $9.1 million total portfolio value.

Customer concentration is absolute—100% of awards and 100% of combined potential value ($9.1 million) derive from HRSA Headquarters alone. The vendor has zero subcontract exposure and performs all work independently. Activity has remained flat across recent years (2022–2026: 6, 5, 6, 6, and 5 awards respectively), with combined dollars obligated at approximately $1 million against $9.1 million potential value. Five awards with ultimate completion dates in the next twenty-four months carry combined potential value of $151 thousand, representing modest recompete exposure tied to the underlying BPA's June 1, 2027 expiration date. The vendor's market position depends entirely on HRSA's continued need for independent medical case review expertise and on successful defense of the parent BPA at its June 2027 recompete.